Trial Profile
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ELOQUENT-1
- Sponsors Bristol-Myers Squibb
- 11 Jan 2022 Status changed from active, no longer recruiting to completed.
- 20 Oct 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 30 Sep 2021 This trial has been completed in Belgium (End Date: 03 Sep 2021), according to European Clinical Trials Database record.